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Abstract: As protein binding of uremic toxins is not well understood, neither in chronic 
kidney disease (CKD) progression, nor during a hemodialysis (HD) session, we studied 
protein binding in two cross-sectional studies. Ninety-five CKD 2 to 5 patients and ten stable 
hemodialysis patients were included. Blood samples were taken either during the routine 
ambulatory visit (CKD patients) or from blood inlet and outlet line during dialysis (HD 
patients). Total (CT) and free concentrations were determined of p-cresylglucuronide (pCG), 
hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and p-cresylsulfate 
(pCS), and their percentage protein binding (%PB) was calculated. In CKD patients, 
%PB/CT resulted in a positive correlation (all p < 0.001) with renal function for all five 
uremic toxins. In HD patients, %PB was increased after 120 min of dialysis for HA and at 
the dialysis end for the stronger (IAA) and the highly-bound (IS and pCS) solutes. During 
one passage through the dialyzer at 120 min, %PB was increased for HA (borderline), IAA, 
IS and pCS. These findings explain why protein-bound solutes are difficult to remove by 
dialysis: a combination of the fact that (i) only the free fraction can pass the filter and (ii) the 
equilibrium, as it was pre-dialysis, cannot be restored during the dialysis session, as it is 
continuously disturbed. 
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1. Introduction 
Uremic syndrome is characterized by the retention of a large number of compounds, which in healthy 
persons are excreted by the kidneys. Some of those retention solutes interact negatively with biological 
functions and are called uremic toxins. These toxins are classified into three groups: the free small  
water-soluble solutes (molecular weight (MW) < 500 Da), the middle molecules (MW > 500 Da) and 
the protein-bound solutes [1,2]. The latter solutes have a protein binding ranging from around 10% (e.g., 
p-cresylglucuronide) to near 100% (e.g., p-cresylsulfate). Many of these protein-bound substances are 
known to exert toxicity in a direct or indirect way [3–5]. However, in our current understanding, toxicity 
is only exerted by the free concentration and not by the protein-bound concentration. 
Since the extent of protein binding depends on the solute concentration, the protein concentration, the 
protein-solute affinity constant and the presence or absence of competing solutes [6], each protein-bound 
uremic toxin binds to the specific proteins to a variable degree. Structural changes of proteins can also 
alter the extent of protein binding, and therefore, it can be hypothesized that the degree of protein binding 
also changes in individual patients with the progression of their chronic kidney disease (CKD),  
as post-translational modifications (oxidation, carbamylation and glycosylation as the most relevant 
processes) of proteins increase as CKD progresses [7]. During hemodialysis (HD), only the free fraction 
can be removed, such that the overall dialyzer clearance depends on the free toxin concentration and on 
the speed of equilibration between bound and free fractions. Free fractions, and with it dialyzer 
clearance, can be increased, for example, by the presence of competing ligands in the serum, like sodium 
octanoate [8,9], or by infusing hypertonic saline at the dialyzer inlet [10–12]. The mechanisms of protein 
binding are, however, not well understood.  
In this study, we evaluated the percentage protein binding at different stages of CKD (i.e., Stages 2 to 5), 
during a hemodialysis session in dialysis patients and in healthy controls. This information might be 
useful in the development of new removal strategies aiming at the optimization of dialysis. 
2. Results and Discussion 
2.1. Patient Characteristics 
Tables 1, 2 and 3 present the demographic and clinical characteristics of the 95 CKD patients, the 10 
HD patients and the 10 healthy controls with normal renal function, respectively. Besides differences in 
renal function among the CKD stages, no dissimilarities were observed among the different CKD stages 
for age, gender, body mass index (BMI), diabetes mellitus (DM) and albumin concentration. 
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Table 1. Demographic and clinical characteristics of the CKD patients. 
Characteristics 
CKD patients 
CKD 2 to 5 CKD 2 CKD 3 CKD 4 CKD 5 
Number, n (%) 95 (100) 11 (11.5) 37 (39) 37 (39) 10 (10.5) 
Age (years) 69 (59;76) 62 (59;71) 74 (61;77) 69 (55;74) 79 (60;83) 
Male gender, n (%) 59 (62) 9 (82) 24 (65) 22 (60) 4 (40) 
BMI (kg/m2) 29 (25;32) 27 (21;29) 29 (25;32) 29 (26;34) 25 (23;30) 
DM, n (%) 45 (47) 4 (36) 19 (51) 18 (49) 4 (40) 
Albumin (g/L) 39 (35;44) 42 (37;47) 38 (35;42) 41 (35;44) 33 (28;39) 
Renal function 1 (mL/min) 32 (20;49) 67 (63;71) 45 (35;51) 22 (19;25) °,+ 11 (9;13) °,+ 
CKD: chronic kidney disease; BMI: body mass index; DM: diabetes mellitus. Median (25th percentile (pct); 
75th pct). ° p < 0.05 versus CKD 2; + p < 0.05 versus CKD 3. 1 Renal function calculated according to the 
Cockcroft-Gault formula.  
Table 2. Demographic and clinical characteristics of the HD patients. 
Characteristics HD patients 
Age (years) 72 (61;78) 
Male gender, n (%) 8 (80) 
Ultrafiltration (mL/min) 4.8 (3.5;8.9) 
BMI (kg/m2) 28 (25;28) 
DM, n (%) 5 (50) 
Total protein (g/L) 60 (58;67) 
Renal function (mL/min) 2.6 (0.0;4.1) 
HD: hemodialysis. Median (25th pct; 75th pct). 
Table 3. Demographic and clinical characteristics of the healthy controls. 
Characteristics Healthy controls 
Age (years) 40 (33;57) 
Male gender, n (%) 4 (40) 
BMI (kg/m2) 23 (19;27) 
Median (25th pct; 75th pct). 
The median percentage protein binding (%PB), the free and total concentration of  
p-cresylglucuronide (pCG), hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and  
p-cresylsulfate (pCS) are shown in Table 4 for an increasing degree of kidney failure, i.e., consecutively 
for the healthy controls, the CKD patients and the HD patients. Since the three groups differ in origin, 
nutrition and hospital center, they were not statistically compared to each other. 
For the healthy controls, the free and total concentration of pCG were below the limit of quantification 
(LOQ), and the %PB could not be calculated. The median %PB was 34% (HA), 83% (IAA), 84% (IS) 
and 94% (pCS). 
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Table 4. Percentage protein binding (%PB), free (CF) and total (CT) concentration of protein-bound solutes in healthy controls with normal 
renal function, in CKD and HD patients (pre-dialysis). 
Uremic 
Toxin  
%PB or 
Concentration 
Healthy controls 
CKD 
HD 
CKD 2 CKD 3 CKD 4 CKD 5 
pCG 
%PB  
CF (mg/dL)  
CT (mg/dL) 
-  
<LOQ  
<LOQ 
7(3;24)  
0.03(0.03;0.04)  
0.03(0.03;0.05) 
10(6;14)  
0.03(0.03;0.04)  
0.04(0.03;0.04) 
9(6;16)  
0.04(0.03;0.07)  
0.05(0.03;0.08) 
8(5;20)  
0.20(0.07;0.25) °,+  
0.25(0.08;0.28) °,+,# 
12(9;19)  
0.31(0.22;0.85)  
0.35(0.25;0.99) 
HA 
%PB  
CF (mg/dL)  
CT (mg/dL) 
34(22;39)  
0.13(0.10;0.16)  
0.17(0.11;0.25) 
38(34;42)  
0.23(0.18;0.38)  
0.39(0.32;0.58) 
38(34;43)  
0.20(0.18;0.32)  
0.33(0.27;0.53) 
38(35;44)  
0.30(0.21;0.42)  
0.51(0.33;0.53) 
43(36;45)  
0.54(0.34;0.69) +  
0.93(0.51;1.25) + 
39(32;54)  
1.59(0.73;3.30)  
2.41(1.57;5.42) 
IAA 
%PB  
CF (mg/dL)  
CT (mg/dL) 
83(78;84)  
0.01(0.01;0.01)  
0.04(0.03;0.05) 
60(56;66)  
0.02(0.02;0.02)  
0.06(0.05;0.07) 
67(61;75)  
0.03(0.02;0.03)  
0.08(0.06;0.12) 
66(61;72)  
0.03(0.03;0.03) °,(+)  
0.09(0.07;0.11) ° 
68(65;71)  
0.03(0.03;0.04) °,+  
0.11(0.10;0.15) ° 
69(63;80)  
0.07(0.04;0.11)  
0.19(0.13;0.33) 
IS 
%PB  
CF (mg/dL) 
CT (mg/dL) 
84(77;88)  
0.02(0.01;0.02)  
0.10(0.06;0.14) 
77(71;83)  
0.03(0.03;0.03)  
0.16(0.11;0.18) 
86(80;90)  
0.03(0.03;0.03)  
0.23(0.16;0.35) 
89(87;92) °,+  
0.04(0.03;0.04) °,+  
0.36(0.28;0.55) °,+ 
92(90;95) °,+  
0.06(0.03;0.08) °,+  
0.79(0.31;1.50) °,+ 
93(90;95)  
0.08(0.04;0.21)  
1.40(0.69;2.18) 
pCS 
%PB  
CF (mg/dL)  
CT (mg/dL) 
94(87;96)  
0.02(0.01;0.02)  
0.31(0.08;0.47) 
93(89;96)  
0.05(0.03;0.07)  
0.47(0.38;0.70) 
97(96;97) °  
0.04(0.02;0.05)  
0.95(0.59;1.37) 
96(95;97)  
0.05(0.03;0.12)  
1.19(0.65;2.52) ° 
94(93;95) +  
0.21(0.12;0.31) +,#  
3.29(1.52;4.47) °,+ 
95(93;97)  
0.06(0.04;0.10)  
2.06(1.14;2.87) 
pCG: p-cresylglucuronide; HA: hippuric acid; IAA: indole-3-acetic acid; IS: indoxyl sulfate; pCS: p-cresylsulfate. LOQ: limit of quantification; Median (25th pct; 75th pct). 
° p < 0.05 versus CKD 2; + p < 0.05 versus CKD 3; # p < 0.05 versus CKD 4; (+) p = 0.061. 
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In the different stages of CKD, the free and total concentrations of the weakly-bound solutes pCG 
and HA were only increased in CKD 5 patients, and for the stronger bound solutes IAA, IS and pCS, 
already at CKD Stage 4. The median percentage protein binding was in the range 7% to 8% (pCG), 38% 
to 43% (HA), 60% to 68% (IAA), 77% to 92% (IS) and 93% to 94% (pCS). For the highly-bound IS, 
%PB was increased in CKD 4 and 5 patients with respect to CKD 2 and 3 patients, while for pCS, %PB 
showed some variation, but without a clear trend. The median %PB in the HD patients was 12% (pCG), 
39% (HA), 69% (IAA), 93% (IS) and 95% (pCS). 
2.2. CKD Patients 
Considering the 95 CKD patients, only %PB of IS showed an (inverse) correlation with renal function 
(R = −0.64; p < 0.001) (Figure S1 in the Supplementary Materials and Table 5). Normalizing %PB for 
total toxin concentration, however, resulted in a positive correlation (all p < 0.001) with renal function 
for all five uremic toxins (Figure 1). 
 
Figure 1. Percentage protein binding (%PB) normalized for total toxin concentration  
(CT) versus renal function of CKD patients for: (A) p-cresylglucuronide; (B) hippuric acid;  
(C) indole-3-acetic acid; (D) indoxyl sulfate; and (E) p-cresylsulfate. 
Table 5 shows the p- and R2-values of the correlation test between %PB and renal function in the  
95 CKD patients. The influence of added covariates CT, diabetes mellitus and the albumin concentration 
was checked, as shown in Table 5. 
The total toxin concentration improved the model (all p < 0.05), except for pCG (Table 5). This result 
is in line with the correlations found in Figure 1. 
When diabetes mellitus was added to the model, only an improvement was found for IAA and IS 
(Table 5). However, a lower R2-value was given compared to CT. 
Including albumin concentration did not improve the correlation between %PB and renal function  
(Table 5), neither did it correlate with %PB (Figure S2). Therefore, the albumin concentration  
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(in this range) did not have an influence on the %PB, as already published for other compounds in  
the literature [13,14]. 
Table 5. p- and R2-values of the correlations between %PB and renal function for pCG,  
HA, IAA, IS and pCS and the influence of added covariates total toxin concentration (CT), 
diabetes mellitus (DM) and albumin concentration in CKD patients. 
Uremic 
Toxin  
%PB versus RF 
Covariates 
CT DM Albumin 
p R2 p R2 p R2 p R2 
pCG 0.65 - 0.081 - 0.288 - 0.91 - 
HA 0.40 - 0.008 0.23 0.623 - 0.49 - 
IAA 0.18 - 0.002 0.71 0.028 0.034 0.85 - 
IS <0.001 0.41 <0.001 0.67 <0.001 0.317 0.77 - 
pCS 0.12 - 0.004 0.16 0.843 - 0.62 - 
p < 0.05 is indicated in bold. R2-values only shown in the case of significant p. 
It is known that post-translational modifications of proteins increase as CKD progresses, with 
carbamylation, oxidation, glycosylation and guanidinylation as the most relevant processes [7,15]. 
Whether our result is influenced by these structural changes in the proteins or whether this is the result 
of competitive binding, leading to an enhanced free toxin concentration, remains unclear. Anyway, the 
presented results are in line with those for highly (around 90%) protein-bound compounds, like valproic 
acid or phenytoin, also showing a decreased protein binding in patients with renal failure [16,17]. 
2.3. HD Patients 
In hemodialysis patients, median pre-dialysis %PB was 12% (pCG), 39% (HA), 69% (IAA), 93% 
(IS) and 95% (pCS). Figure 2 and Table 6 show %PB determined at the inlet of the dialyzer, at the start 
(0 min) of the hemodialysis session and after 60, 120 and 240 min. 
The total and free toxin concentrations were decreased from 120 min on for pCG, HA and pCS.  
For IAA, only the total concentration decreased from 120 min on and for IS, only the free concentration  
(Table 6). No differences in %PB were observed during the HD session for the weakly-bound pCG.  
For HA, %PB was increased after 120 and 240 min versus HD start, while for the stronger (IAA)  
and highly-bound (IS and pCS) solutes, this increase was only significant after 240 min (Figure 2  
and Table 6). 
Changes in percentage protein binding from the dialyzer inlet towards the outlet as measured at  
120 min after dialysis start are depicted in Figure 3. For the weakly-bound pCG, passage through the 
dialyzer did not influence the percentage binding. For HA, the %PB was increased with a borderline 
significance (p = 0.066). The percentage protein binding for the stronger (IAA) and the highly-bound 
(IS and pCS) solutes was significantly increased from dialyzer inlet to outlet at 120 min.  
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Figure 2. Percentage protein binding at different time points during a hemodialysis (HD) 
session for: (A) p-cresylglucuronide; (B) hippuric acid; (C) indole-3-acetic acid; (D) indoxyl 
sulfate; and (E) p-cresylsulfate. * p < 0.05; o: outlier; x: extreme. 
Table 6. Percentage protein binding, free and total concentration of protein-bound solutes in 
HD patients at different time points during an HD session. 
Uremic 
Toxin 
%PB or 
Concentration 
0 min 60 min 120 min 240 min 
pCG 
%PB  
CF (mg/dL)  
CT (mg/dL) 
12(9;19)  
0.31(0.22;0.85)  
0.35(0.25;0.99) 
13(10;15)  
0.14(0.11;0.44) 
0.17(0.12;0.45)
10(13;20)  
0.11(0.07;0.29) °  
0.14(0.08;0.36) ° 
11(5;19)  
0.08(0.04;0.16) °,+ 
0.10(0.05;0.19) °,+ 
HA 
%PB  
CF (mg/dL)  
CT (mg/dL) 
39(32;54)  
1.59(0.73;3.30)  
2.41(1.57;5.42) 
49(43;54)  
0.91(0.41;1.84) 
1.42(0.99;3.52)
50(47;60) °  
0.70(0.44;1.37) ° 
1.37(0.97;2.55) ° 
54(39;58) °  
0.42(0.32;0.82) °,+ 
0.95(0.61;1.49) °,+ 
IAA 
%PB  
CF (mg/dL)  
CT (mg/dL) 
69(63;80)  
0.07(0.04;0.11)  
0.19(0.13;0.33) 
77(72;82)  
0.04(0.02;0.08) 
0.14(0.10;0.26)
80(77;86)  
0.03(0.02;0.06)  
0.13(0.10;0.23) ° 
83(78;87) ° 
0.03(0.02;0.07) °  
 0.10(0.08;0.16) °,+ 
IS 
%PB  
CF (mg/dL)  
CT (mg/dL) 
93(90;95)  
0.08(0.04;0.21)  
1.40(0.69;2.18) 
94(91;95)  
0.06(0.04;0.16) 
1.14(0.60;1.97)
95(94;95)  
0.06(0.03;0.12) °  
1.06(0.56;1.75)  
95(95;96) °  
0.03(0.02;0.07) °,+ 
0.72(0.48;1.47) °,+ 
pCS 
%PB  
CF (mg/dL)  
CT (mg/dL) 
95(93;97)  
0.12(0.10;0.24)  
2.76(1.75;4.25) 
95(92;96)  
0.13(0.09;0.19) 
2.46(1.45;3.70)
96(95;97)  
0.09(0.07;0.14) °  
2.27(1.32;3.41) ° 
97(97;97) °,+  
0.06(0.04;0.10) °,+ 
2.06(1.14;2.87) °,+ 
° p < 0.05 versus 0 min; + p < 0.05 versus 60 min. Median (25th pct; 75th pct). 
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Figure 3. Percentage protein binding at the dialyzer inlet versus outlet after 120 min since 
dialysis start for: (A) p-cresylglucuronide; (B) hippuric acid; (C) indole-3-acetic acid;  
(D) indoxyl sulfate; and (E) p-cresylsulfate. ** p < 0.05 versus the inlet; * p = 0.066  
versus the inlet; o: outlier; x: extreme. 
This is the first time that it has been demonstrated that the percentage protein binding for stronger 
bound solutes changes during dialysis, and this is both within the dialyzer itself during a single passage 
and within a patient (i.e., during the course of the dialysis session). The influence of hemoconcentration 
on these observations was checked by a correlation test between the change in %PB and the change in 
total protein concentration at the inlet and outlet of the dialyzer, but no significant correlation was found 
(Figure S3). Neither can this be explained by changes in pH, since we only observed limited pH changes 
during the course of a dialysis session.  
A possible explanation might be found in the hypothesis that the physicochemical bond of the toxin 
with its protein is strong. As a consequence, the equilibrium reaction is too slow to restore the free toxin 
concentration within the time frame of a single passage through the dialyzer and even within the time 
frame of a dialysis session once the pool of available pre-dialysis free fraction has been removed. 
Therefore, we calculated the reduction ratio (RR) for both total and free toxin concentration to check 
this hypothesis. The RR is graphically presented in Figure 4 for pCG, HA, IAA, IS and pCS at 60, 120 
and 240 min since the start of the dialysis session. The slopes of free and total RR are borderline 
significant for IS (p = 0.061) and significantly different for pCS (p < 0.001).  
The difference in RR between free and total concentrations might imply that the equilibrium could 
not be formed during the course of the dialysis session. For the weakly-bound pCG, for example, around 
90% of the total concentration is unbound and is thus easily removed by the dialyzer, resulting in a 
comparable total and free reduction ratio. The RR of the highly-bound pCS, on the other hand, is different 
for free and total concentrations, and within the four hours of dialysis, the RR of the total concentration 
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cannot follow the RR of the free concentration (around 4%). The equilibrium between free and bound 
pCS is continuously disturbed because of the dynamic process of dialysis. Therefore, the equilibrium  
(as it was pre-dialysis) cannot be restored during the dialysis session and explains the observations in 
Figures 2 and 3. 
 
Figure 4. Reduction ratio for total ( ) and free ( ) toxin concentration at different time 
points during an HD session for: (A) p-cresylglucuronide (free: y = 0.15x + 41; R2 = 0.96; 
total: y = 0.15x + 42; R2 = 0.99); (B) hippuric acid (free: y = 0.14x + 37; R2 = 1.00; total:  
y = 0.16x + 27; R2 = 1.00); (C) indole-3-acetic acid (free: y = 0.14x + 30; R2 = 0.96; total:  
y = 0.10x + 16; R2 = 0.99); (D) indoxyl sulfate (free: y = 0.19x + 8.7; R2 = 1.00; total:  
y = 0.11x + 11; R2 = 1.00); and (E) p-cresylsulfate (free: y = 0.21x + 6.4; R2 = 1.00; total:  
y = 0.10x + 6.5; R2 = 1.00). 
Both aspects, i.e., (i) only the free fraction can be removed and (ii) the bound fraction is released 
slowly, are the main determinants for the limited removal of solutes during dialysis. This fits with the  
multi-pass device observations, as described by Eloot et al., where removal of protein-bound solutes was 
limited to the first two hours of dialysis [18]. In a kinetic modelling study from our group [19] based on 
intradialytic concentrations, we found an inverse correlation between dialyzer clearance and the %PB. 
Furthermore, total distribution volumes and intercompartment clearances (except for pCG), which are 
representative for solute retardation inside the patients, were also inversely correlated with the %PB. 
Thus, the present findings are in full agreement with those in the kinetic analysis.  
It can be stated that during dialysis, first the free fraction will be removed and will cause a 
disequilibrium with the bound fraction, as well as with concentrations in the extra vascular spaces. This 
results in a continuous release of the bound fraction, respectively inflow from the extravascular space. 
These kinetics of protein-bound solutes were already extensively studied by our group showing the 
multi-compartmental behavior with vascular and extravascular spaces [20].  
(C) Indole-3-Acetic Acid (D) (E)Indoxyl Sulfate p-Cresylsulfate
(B) Hippuric Acid(A) p-Cresylglucuronide
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Enhancing the filtration of proteins is cumbersome, as this would result in hypoproteinemia. 
However, it can be hoped that strategies could be developed that change the strength of the physical 
bond between the toxin and its ligand, to increase the free (dialyzable) solute concentration. 
Recent research suggested a novel approach to increase the free fraction of the protein-bound solutes 
phenyl acetic acid (PAA), indoxyl sulfate and p-cresylsulfate during dialysis by infusing a hypertonic 
solution at the dialyzer inlet [10–12]. This increased the local ionic strength at the blood inlet of the 
dialyzer, resulting in an enhanced release of uremic toxin from its protein binding site, most pronounced 
for the middle bound PAA (%PB around 60%). With this approach, the clearance during in vitro dialysis 
was relatively most beneficial for the highly-bound IS and pCS [10]. These in vitro results might be 
promising, but the absence of hemolysis due to hyperosmolarity needs to be further investigated in vivo. 
3. Experimental Section 
To calculate the percentage protein binding in CKD patients, data were taken from a cross-sectional 
study including 95 patients with confirmed diagnosis of CKD Stages 2 to 5. To unravel changes in 
protein binding in the hemodialyzer, as well as during the course of a hemodialysis session, data were 
taken from a second cross-sectional study including 10 stable HD patients. Data from ten healthy 
controls with normal renal function were also collected to cover the range (healthy-CKD-HD) of free 
and total toxin concentrations, as well as for protein binding. 
3.1. Patients and Sampling Protocol 
CKD patients: 95 CKD patients (CKD Stages 2 to 5) were included from Amiens University Hospital 
(France), in whom concentrations of uremic retention solutes were evaluated for their relation to clinical 
outcomes [21–23]. These patients were older than 40 years and had a confirmed diagnosis of CKD (renal 
function below 90 mL/min, calculated in the aforementioned study according to the Cockcroft-Gault 
formula [24]). Exclusion criteria included the presence of chronic inflammatory disease, atrial 
fibrillation, complete heart block, abdominal aorta aneurysm, aortic and/or femoral artery prosthesis, 
primary hyperparathyroidism, kidney transplantation, on dialysis and any acute cardiovascular event in the 
3 months before screening for inclusion. Blood samples were taken in the morning on the occasion of a 
visit at the outpatient clinic.  
HD patients: 10 stable hemodialysis patients were included from Ghent University Hospital. 
Exclusion criteria were active infection, pregnancy, unstable condition, vascular access problems and 
age below 18 years. During the experimental session at midweek, conventional two needle/lumen HD 
was performed for 240 min using high-flux dialyzers: FX800 (n = 6) (Fresenius Medical Care, Bad 
Homburg, Germany), Evodial (n = 1) (Gambro, Lund, Sweden), Xenium 210 (n = 1) (Baxter, Dearfield, 
IL, USA), Phylter HF17G (n = 1) and Phylter HF17SD (n = 1) (Bellco, Mirandola, Italy) in a diffusive 
mode. Blood and dialysate flows were set at 300 and 700 mL/min, respectively, while ultrafiltration rates 
were set according to the needs of the patients. Nine patients had a well-functioning fistula and one 
patient a Bard Optiflow central venous catheter (Bard, Covengton, GA, USA) as vascular access. 
Residual renal function was calculated as the arithmetic mean of the creatinine and urea clearance, 
calculated from the interdialytic urine collection (volume and concentration) and blood concentrations at 
the start and end of the interdialytic period [25]. During the experimental session, blood samples were 
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collected at the start of the session from the vascular access and from the inlet blood line after 60 and 
120 min, and immediately after discontinuation of the dialysis session (at 240 min). Blood samples were 
also collected from the outlet blood line after 120 min since the start of the dialysis session. 
Both studies were approved by the local ethical committees (Comité de protection des Personnes 
Nord-Ouest II, CHU Amiens, Amiens, France, 06H3 for CKD patients, and Ghent University Hospital, 
Ghent, Belgium, UZG 2008/081 for HD patients), performed in accordance with the principles of the 
Declaration of Helsinki, and all patients gave their written informed consent. 
Healthy Controls: Data from 10 healthy volunteers with normal renal function were collected  
at Ghent University Hospital. Subjects who were smoking, had an infection, were pregnant or on 
medication were excluded. 
3.2. Laboratory 
All blood samples were immediately centrifuged after sampling, and serum was stored at −80 °C until 
batch analysis. 
Concentrations of protein-bound uremic toxins were determined by reversed-phase high  
performance liquid chromatography (RP-HPLC), as described earlier [26,27]. The solutes analyzed were 
p-cresylglucuronide (pCG, MW: 284.3 Da), hippuric acid (HA, MW: 179.2 Da), indole-3-acetic acid 
(IAA, MW: 174.2 Da), indoxyl sulfate (IS, MW: 212.2 Da) and p-cresylsulfate (pCS, MW: 187.2 Da). To 
determine the total concentration, serum samples were first deproteinized by heat denaturation prior to 
HPLC analysis [27]. HA was analyzed by UV detection at 254 nm, whereas pCG and pCS (λexc. = 265 nm, 
λem = 290 nm) and IAA and IS (λexc. = 280 nm, λem = 340 nm) were determined by fluorescence  
detection [26,27]. To obtain free fractions, untreated serum samples were filtered through a Centrifree® 
filter device (Millipore Billerica, MA, USA) prior to heating [26]. Albumin levels in serum from CKD 
patients were assayed in a biochemistry laboratory using standard autoanalyzer techniques (the Modular 
IIP system, Roche Diagnostics, Basel, Switzerland) [21–23]. In HD patients, total protein concentration 
in serum was analyzed according to standard methods (Biuret reaction). 
3.3. Calculations 
Percentage protein binding (%PB) was calculated from the measured total (CT) and free (CF) 
concentrations as %PB = [1 − (CF/CT)] × 100%. 
The reduction ratio (RR) for the free and total concentration in HD patients was determined from the 
concentration at the start of the dialysis session (Cpre) and after time t = 60, 120 and 240 min (Ct) as  
RR = [Cpre − (Ct/Cpre)] × 100%.  
3.4. Statistical Analysis 
Statistical evaluation was performed with SPSS Statistics 22 (2013, Armonk, NY, USA). Data were 
checked for normality. As most numeric data were not normally distributed, data were expressed as the 
median (25th percentile (pct); 75th pct). To compare independent categorical data, Fisher’s exact test 
was performed. Differences between more than two groups of unpaired data (CKD data) were checked 
with a Kruskal–Wallis test (with multiple comparisons and Bonferroni correction). Paired comparisons 
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(HD data) between more than two groups were made with a Friedman test (with multiple comparisons 
and Bonferroni correction). To evaluate the difference between two paired groups, the Wilcoxon  
signed-rank test was applied. Spearman’s rho test was performed to check correlation (all presented p- 
and R-values are Spearman’s rho values, unless stated otherwise). A univariate general linear model 
(GLM) was used with covariates (CT, DM and albumin concentration) to check any improvements of 
the correlation between renal function and %PB. A linear regression procedure was used to check 
differences in regression coefficients between two groups (reduction ratio). p < 0.05 was considered 
significant, and all tests were two-tailed. 
4. Conclusions 
In this study, we explored the protein binding of uremic toxins in patients with different stages  
of CKD and during a hemodialysis session. The observed change in protein binding in CKD patients 
with advanced CKD stages might be due to post-translational modifications of proteins, characteristic 
for CKD progression. The observed results in HD patients explain why protein-bound solutes are 
difficult to remove by dialysis: a combination of the fact that (i) only the free fraction can pass the filter 
and (ii) the equilibrium, as it was pre-dialysis, cannot be restored during the dialysis session, as it is 
continuously disturbed. This can be explained by the kinetics of these protein-bound uremic toxins: once 
the free fraction is removed, the equilibrium with the bound fraction and the extra vascular space is 
disturbed, causing a potential release of the bound fraction, respectively inflow from the extravascular 
space [20]. 
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